Fresenius SE & Co KGaA (FRE) PT Set at €58.00 by Nord/LB

Fresenius SE & Co KGaA (FRA:FRE) has been assigned a €58.00 ($67.44) price objective by stock analysts at Nord/LB in a research report issued on Thursday, Borsen Zeitung reports. The brokerage currently has a “buy” rating on the stock. Nord/LB’s target price would indicate a potential upside of 12.77% from the stock’s current price.

FRE has been the subject of a number of other research reports. Barclays set a €51.00 ($59.30) target price on Fresenius SE & Co KGaA and gave the company a “neutral” rating in a research note on Monday, February 18th. Goldman Sachs Group set a €52.00 ($60.47) target price on Fresenius SE & Co KGaA and gave the company a “buy” rating in a research note on Friday, March 22nd. Berenberg Bank set a €70.95 ($82.50) target price on Fresenius SE & Co KGaA and gave the company a “buy” rating in a research note on Thursday. UBS Group set a €46.00 ($53.49) price target on Fresenius SE & Co KGaA and gave the company a “neutral” rating in a report on Wednesday, January 9th. Finally, Morgan Stanley set a €45.00 ($52.33) price target on Fresenius SE & Co KGaA and gave the company a “neutral” rating in a report on Tuesday, April 16th. Ten equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of €59.23 ($68.88).

FRE stock opened at €51.43 ($59.80) on Thursday. Fresenius SE & Co KGaA has a 1 year low of €60.16 ($69.95) and a 1 year high of €80.00 ($93.02).

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

See Also: What is included in the gross domestic product?

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.